BioLife Solutions to Attend and Present at Upcoming Scientific and Investor Conferences


BOTHELL, Wash., Aug. 12, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that representatives of the Company will be attending, exhibiting, and/or presenting at the following upcoming scientific and investor conferences:

The Bioprocessing Summit

August 12th-16th, 2019

 Seaport World Trade Center, Boston, MA


21st Annual H.C. Wainwright & Co. Global Investment Conference

September 8th-10th, 2019

Lotte New York Palace Hotel, New York, NY


3rd Annual Janney Healthcare Conference

September 9th-10th, 2019

The Union League Club, New York, NY


Biotech Week Boston –  Cell & Gene Therapy Bioprocessing & Commercialization

September 9th-12th, 2019

Boston Convention & Exhibition Center, Boston, MA


CAR-TCR Summit

September 10th-13th, 2019

Seaport World Trade Center, Boston, MA


ISCT North America 2019 Regional Meeting

September 13th-15th, 2019

Monona Terrace Community and Convention Center, Madison, WI


Cord Blood Connect

September 13th-15th, 2019

Loews Hotel, Miami Beach, FL


Cell and Gene Meeting on the Mesa

October 2nd-4th, 2019

Park Hyatt Aviara Resort, Carlsbad, CA


BEST Collaborative

October 16th – 17th, 2019

Marriott Riverwalk, San Antonio, TX


AABB Annual Meeting

October 19th-22nd, 2019

Henry B. Gonzales Convention Center, San Antonio, TX


Stifel 2019 Healthcare Conference

November 19th-21st, 2019

Lotte New York Palace Hotel, New York, NY


TERMIS Americas

December 2nd-5th, 2019

 Loews Sapphire Falls Resort, Orlando, FL


Cellular Therapies and Transfusion Medicine in Trauma and Critical Care (CTTACC) 2019

December 11th – 13th, 2019

Rancho Bernardo Inn, San Diego, CA

Cell and gene therapy tools. (PRNewsfoto/BioLife Solutions, Inc.)

About BioLife Solutions

BioLife Solutions is a leading supplier of cell and gene therapy tools. Our proprietary CryoStor® freeze media and HypoThermosol® shipping and storage media are highly valued in the regenerative medicine, biobanking and drug discovery markets. These biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our recently acquired ThawSTAR® family of automated cell thawing products and evo cold chain management system reduce therapeutic and economic risk for cell and gene therapy developers by reducing the potential of administering a non-viable dose. For more information please visit, and follow BioLife on Twitter.

Media & Investor Relations

Roderick de Greef

Chief Financial Officer

(425) 686-6002



SOURCE BioLife Solutions, Inc.

Print Friendly